Determination of Recurrent/Residual Cin-II And Cin-III After Leep. Cytology or Hpv-Dna?

DİLEK, Saffet; DİLEK, Talat Umut Kutlu; DORUK, Arzu; DURUKAN, Hüseyin; ÇOBAN, Özgür

Determination of Recurrent/Residual Cin-II And Cin-III After Leep. Cytology or Hpv-Dna?

Özgür ÇOBAN, (Mersin Üniversitesi, Tıp Fakültesi, Kadın Hastalıkları ve Doğum Bölümü,Mersin, Türkiye)

Hüseyin DURUKAN, (Mersin Üniversitesi, Tıp Fakültesi, Kadın Hastalıkları ve Doğum Bölümü,Mersin, Türkiye)

Talat Umut Kutlu DİLEK, (Mersin Üniversitesi, Tıp Fakültesi, Kadın Hastalıkları ve Doğum Bölümü,Mersin, Türkiye)

Arzu DORUK, (Mersin Üniversitesi, Tıp Fakültesi, Kadın Hastalıkları ve Doğum Bölümü,Mersin, Türkiye)

Saffet DİLEK (Mersin Üniversitesi, Tıp Fakültesi, Kadın Hastalıkları ve Doğum Bölümü,Mersin, Türkiye)

Zeynep Kamil Tıp Bülteni

2 0

Yıl: 2016 Cilt: 47 Sayı: 4 Sayfa Aralığı: 101 - 105 Metin Dili: İngilizce İndeks Tarihi: 29-07-2022

Determination of Recurrent/Residual Cin-II And Cin-III After Leep. Cytology or Hpv-Dna?

Öz:

Objective: Having some advantages, LEEP becomes thestandard treatment of CIN-II and III lesions. However,failure to treatment after LEEP is also seen as in othertreatment methods. This study aims to determine the value of cervical cytology, surgical margin positivity andHPV-DNA testing for determination of residual or recurrent disease in patients undergone LEEP with the diagnosis of CIN II or III.Material and Method: Colposcopy directed biopsy andendocervical curettage applied 77 cases six months afterinitial LEEP treatments were retrospectively analyzed.Histological examination is used in order to determineresidual/recurrent disease. Cytology and HPV-DNA PCRtests after six months and initial surgical margin positivity at the time of LEEP were all compared.Results: In 14 (18.1%) of the 77 cases, residual/recurrent disease was determined. HR-HPV was positive in13 (17%) and negative in 64 (83%). Recurrent/residualdisease rate was found to be 12/13 (92%) in HR-HPVpositive cases and 2/64 (3%) in HR-HPV negative cases.Out of 25 patients who were surgical margin positive,recurrent/residual disease was determined in 7 (28%).Cytology was positive in 26 (33.8%) cases. Recurrent/residual disease was determined in 2 of the cytology negative and in 12 of the cytology positive cases.In prediction of residual/recurrent disease, HPVtesting was found to be superior to surgical margin positivity or conventional cytology.Conclusion: HPV test may be considered primarily fordetermination of treatment failures after LEEP.

Anahtar Kelime:

Konular: Cerrahi

Leep Sonrası Rekürren/Rezidüel CIN 2-3 Belirlenmesi. Sitoloji mi, Hpv-Dna mı?

Öz:

Amaç: Bazı avantajlara sahip olan LEEP uygulaması CIN-II ve III lezyonlarının standart tedavisi haline gelmiştir. Ne yazık ki,diğer tedavi yöntemlerinde olduğu gibi tedavi başarısızlıkları LEEP uygulaması sonrasında da görülebilmektedir. Bu çalışma CIN II veya III nedeniyle LEEP yapılan olgularda rekürren/ rezidüel hastalık belirlenmesinde servikal sitoloji, cerrahi sınır pozitifliği ve HPV DNA testinin değerini ortaya koymayı amaçlamaktadır. Gereç ve Yöntem: LEEP tedavisi uygulanmış ve altı ay sonrasında kolposkopi yönlendirilmiş biyopsi ve endoservikal küretaj yapılmış 77 olgu retrospektif olarak incelendi. Rekürren / rezidüel hastalık tespiti için histolojik inceleme uygulanmıştı. LEEP esnasındaki cerrahi sınır pozitifliği, altı ay sonrasında alınan sitoloji ve HPV DNA PCR test sonuçları karşılaştırmaya dahil edildi. Bulgular: Rekürren / rezidüel hastalık 77 olgunun 14’ünde (%18,1) belirlenmiştir. HR-HPV 13 (%17) olguda pozitif ve 64 (%83) olguda negatifti. Rekürren / rezidüel hastalık oranı HR-HPV pozitif olgularda 12/13 (%92), ve HR-HPV negatif olgularda 2/64 (%3) olarak saptandı. Cerrahi sınır pozitifliği olan 25 olgunun ise 7’sinde (%28) rekürren / rezidüel hastalık saptandı. Sitoloji 26 (%33,8) olguda pozitifti. . Rekürren / rezidüel hastalık sitolojis negatif olan 2 olguda ve sitolojisi pozitif olan 12 olguda saptandı. Rekürren / rezidüel hastalık öngörmede HPV testinin cerrahi marjin pozitifliğinden veya konvansiyonel sitolojiden daha üstün olduğu görüldü. Sonuç: HPV testi LEEP sonrası tedavi başarısızlığını belirlemede ilk planda kullanılabilir. Anahtar Kelimeler: HPV; Rekürren rezidüel hastalık; CIN 2; CIN 3; LEEP

Anahtar Kelime:

Konular: Cerrahi

Belge Türü: Makale Makale Türü: Araştırma Makalesi Erişim Türü: Erişime Açık

Garcia-Hernandez E, Gonzalez-Sanchez JL, And- rade-Manzano A et al. Regression of papilloma high-gra- de lesions (CIN 2 and CIN 3) is stimulated by therapeutic vaccination with MVL E2 recombinant vaccine. Cancer Gene Ther. 2006 June;13(6):592-7.
Pinda AV, Crum CP, Natural history of cervical ne- oplasia :defining progression and its consequences. Clin Obstet Gynecol. 2000 Jun;43(2):352-62.
Nuovo J, Melnikow J, Willan AR, Chan BK Treat- ment Outcomes for squamous intraepithelial lesion. Int J Gynaecol Obstet. 2000 Jan;68(1):2553-68.
Wright TC Jr, Massad LS, Dunton CS, Spitzer M, Wilkinson EJ, Solomon D. 2006 Consensus guidelines for the management of woman with cervical intraepithelial neoplasia or adenocarcinoma in situ. J Low Genit Tract Dis 2007 Oct;11(4):223-239.
Costa S, De Simone P, Venturoli S et al. Factors predicting human papillomavirus, clearance in cervical intraepithelial neoplasia lesion treated by conization Gy- necol Oncol. 2003 Aug;90(2):358-365.
Strander B, Ryd W, Wallin KL, Varelby B, Zheng B et al. Does HPV status 6-12 months after treatment of high grade dysplasia in the uterine cervix predict long term recurrence Eur J Cancer 2007 Aug;43(12):1849
Sarian LO, Derchain SF, Andrade LA,Tambas- cia J, Morris SS et al. HPV DNA test and PAP smear in detection of residual/recurrent disease following loop electrosurgical excision procedure of high-grade cer- vical intraepithelial neoplasia. Gynecol Oncol. 2004 Jul;94(1):181-186.
Aschkenazi-Steinberg SO, Spitzer BJ, Spitzer M, Lesser M, The clinical usefulness of human papillomavi- rus testing in the follow-up of women after treatment for cervical intraepithelial neoplasia. J Low Genit Tract Dis. Oct;8(4):304-307. Zielinski GD, Bais AG, Helmerhorst TJ, Verheijen RH et al. HPV testing and monitoring of women after treatment of CIN-3 A review of the literature and meta-a- nalysis. Obstet Gynecol Surv. 2004 Jul;59(7):543-553.
Kang WD, Oh MJ, Kim SM, Nam JH et al. Signi- ficance of human papilloma virus genotyping with hi- gh-grade cervical intraepithelial neoplasia treated by loop electrosurgical excision procedure Am J Obstet Gy- necol. 2010 Jul;203(1):72:1-6.
Lequevaque P, Motton S, Decharme A, Soule-Tholy M, Escourrou G, Hoff J. Predictors of recurrence in high grade cervical lesions and plan of management Euro J Surg Oncol. 2010 Nov;36(11):1073-1079.
Fuste P, Bellosillo B, Santamaria X, Mancebo G, Marinoso L et al. HPV determination in the control after leep due to CIN II-III: prospective study and predictive model. Int J Gynecol Pathol. 2009 Mar;28(2):120-126.
Park JY, Bae J, Lim MC, Lim SY, Lee DO, Kang S, Park SY, et al. Role of high risk human papillomavirus test in the follow-up of patients who underwent coniza- tion of the cervix for cervical intraepithelial neoplasia J Gynecol Oncol. 2009 Jun;20(2):86-90.
Murdoch JB, Morgan PR, Lopes A, Monaghan JM, Hystological incomplet excision of CIN after large loop excision of the transformation zone (LLETZ). Merits ca- reful follow up, not treatment. Br J Obstet Gynecol. 1992 Dec;99(12):990-993.
Kalagirou D, Antoniou G, Karakitsos P, Botsis D, et al. Predictive factors used to justify hysterectomy after loop conization : increasing age and severity of disease. Eur J Gynecol Oncol. 1997;18(2):113-116.
Moore BC, Higgins RV, Laurent SL, Marroum M, et al. Predictive factors from cold knife conization for resi- dual cervical intraepithelial neoplasia in subsequent hys- terectomy. Am J Obstet Gynecol. 1995 Aug;173(2):361
Ayhan A, Boynukalin FK, Güven S, Dogan NU, Esinler I, Usubutun A. Repeat LEEP conization in pa- tients with cervical intraepithelial neoplasia grade 3 and post ectocervical margins. Int J Gynaecol Obstet. 2009 Apr;105(1):14-17.
Gardeil F, Barry-Walsch C, Prendiville W, Clinch J. et al. Persistent intraepithelial neoplasia after excision for cervical intraepithelial neoplasia grade III. Obstet Gynecol. 1997 Mar;89(3):419-422.
Wu D, Zheng Y, Chen W, Guo C, Yu J, Chen G, et al. Prediction of residual/recurrent disease by HPV genoty- pe after loop excision procedure for high grade cervical intraepithelial neoplasia with negative margins. Aust N Z J Obstet Gynaecol. 2011 Apr;51(2):114-118.
Bae JH, Kim CJ, Park TC, Namkoong SE, Park JS, Persistance of human papillomavirus as a predi- ctor for treatment failure after loop electrosurgical excision procedure. Int J Gynecol Cancer. 2007 Nov- Dec;17(6):1271-1277.
Brismar S, Johansson B, Borjesson M, Arbyn M, Anderson S. Follow up after treatment of cervical intrae- pithelial neoplasia by human papillomavirus genotyping. Am J Obstet Gynecol. 2009 Jul;201(1);17:1-8.

APA	ÇOBAN Ö, DURUKAN H, DİLEK T, DORUK A, DİLEK S (2016). Determination of Recurrent/Residual Cin-II And Cin-III After Leep. Cytology or Hpv-Dna?. , 101 - 105.
Chicago	ÇOBAN Özgür,DURUKAN Hüseyin,DİLEK Talat Umut Kutlu,DORUK Arzu,DİLEK Saffet Determination of Recurrent/Residual Cin-II And Cin-III After Leep. Cytology or Hpv-Dna?. (2016): 101 - 105.
MLA	ÇOBAN Özgür,DURUKAN Hüseyin,DİLEK Talat Umut Kutlu,DORUK Arzu,DİLEK Saffet Determination of Recurrent/Residual Cin-II And Cin-III After Leep. Cytology or Hpv-Dna?. , 2016, ss.101 - 105.
AMA	ÇOBAN Ö,DURUKAN H,DİLEK T,DORUK A,DİLEK S Determination of Recurrent/Residual Cin-II And Cin-III After Leep. Cytology or Hpv-Dna?. . 2016; 101 - 105.
Vancouver	ÇOBAN Ö,DURUKAN H,DİLEK T,DORUK A,DİLEK S Determination of Recurrent/Residual Cin-II And Cin-III After Leep. Cytology or Hpv-Dna?. . 2016; 101 - 105.
IEEE	ÇOBAN Ö,DURUKAN H,DİLEK T,DORUK A,DİLEK S "Determination of Recurrent/Residual Cin-II And Cin-III After Leep. Cytology or Hpv-Dna?." , ss.101 - 105, 2016.
ISNAD	ÇOBAN, Özgür vd. "Determination of Recurrent/Residual Cin-II And Cin-III After Leep. Cytology or Hpv-Dna?". (2016), 101-105.

APA	ÇOBAN Ö, DURUKAN H, DİLEK T, DORUK A, DİLEK S (2016). Determination of Recurrent/Residual Cin-II And Cin-III After Leep. Cytology or Hpv-Dna?. Zeynep Kamil Tıp Bülteni, 47(4), 101 - 105.
Chicago	ÇOBAN Özgür,DURUKAN Hüseyin,DİLEK Talat Umut Kutlu,DORUK Arzu,DİLEK Saffet Determination of Recurrent/Residual Cin-II And Cin-III After Leep. Cytology or Hpv-Dna?. Zeynep Kamil Tıp Bülteni 47, no.4 (2016): 101 - 105.
MLA	ÇOBAN Özgür,DURUKAN Hüseyin,DİLEK Talat Umut Kutlu,DORUK Arzu,DİLEK Saffet Determination of Recurrent/Residual Cin-II And Cin-III After Leep. Cytology or Hpv-Dna?. Zeynep Kamil Tıp Bülteni, vol.47, no.4, 2016, ss.101 - 105.
AMA	ÇOBAN Ö,DURUKAN H,DİLEK T,DORUK A,DİLEK S Determination of Recurrent/Residual Cin-II And Cin-III After Leep. Cytology or Hpv-Dna?. Zeynep Kamil Tıp Bülteni. 2016; 47(4): 101 - 105.
Vancouver	ÇOBAN Ö,DURUKAN H,DİLEK T,DORUK A,DİLEK S Determination of Recurrent/Residual Cin-II And Cin-III After Leep. Cytology or Hpv-Dna?. Zeynep Kamil Tıp Bülteni. 2016; 47(4): 101 - 105.
IEEE	ÇOBAN Ö,DURUKAN H,DİLEK T,DORUK A,DİLEK S "Determination of Recurrent/Residual Cin-II And Cin-III After Leep. Cytology or Hpv-Dna?." Zeynep Kamil Tıp Bülteni, 47, ss.101 - 105, 2016.
ISNAD	ÇOBAN, Özgür vd. "Determination of Recurrent/Residual Cin-II And Cin-III After Leep. Cytology or Hpv-Dna?". Zeynep Kamil Tıp Bülteni 47/4 (2016), 101-105.